Sotagliflozin is in clinical development for the treatment of type 2 diabetes mellitus (T2DM). T2DM is a common, lifelong condition that causes the level of glucose in the blood to become too high. It is caused by problems with a chemical in the body (hormone) called insulin, which is produced in the pancreas and is responsible for controlling the amount of glucose in the blood. There are two main types of diabetes: type 1 – where the pancreas does not produce any insulin, and type 2 – where the pancreas does not produce enough insulin or body cells do not react to insulin.
Sotagliflozin is one of a new class of drugs that increase elimination of glucose in the urine. They offer the advantages of a reduced risk of low blood sugar. Sotagliflozin reduces the reabsorption of glucose from the intestines and kidneys, thus improving blood glucose control in diabetes mellitus. If licensed, sotagliflozin will offer an additional treatment option for patients with T2DM.
Treosulfan in addition to fludarabine is in clinical development for paediatric non-malignant disease prior to allogeneic stem cell transplant. Treosulfan is a medicine given to patients before they have a bone marrow transplant from a donor known as ‘allogeneic haematopoietic stem cell transplantation’. It is used as a ‘conditioning’ treatment to clear the patient’s bone marrow and make room for the transplanted bone marrow cells, which can then produce healthy blood cells. Treosulfan is used together with another medicine called fludarabine for the treatment of a variety of disorders that require a bone marrow transplant.